Innoviva, Inc. $INVA Stock Holdings Lowered by Royce & Associates LP

Royce & Associates LP decreased its position in shares of Innoviva, Inc. (NASDAQ:INVA – Free Report) by 4.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,118,257 shares of the biotechnology company’s stock after selling 54,433 shares during the quarter. Royce & Associates LP owned 1.55% of Innoviva worth $23,718,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Dimensional Fund Advisors LP raised its holdings in Innoviva by 1.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 4,436,427 shares of the biotechnology company’s stock worth $103,366,000 after acquiring an additional 76,026 shares during the last quarter. BlackRock Inc. bought a new position in Innoviva in the 2nd quarter valued at approximately $77,562,000. Bank of America Corp DE purchased a new stake in Innoviva during the 2nd quarter valued at $37,873,000. Deutsche Bank AG purchased a new stake in Innoviva during the 2nd quarter valued at $20,847,000. Finally, William Blair Investment Management LLC boosted its stake in Innoviva by 29.7% during the 3rd quarter. William Blair Investment Management LLC now owns 832,881 shares of the biotechnology company’s stock valued at $17,665,000 after purchasing an additional 190,705 shares during the last quarter. Institutional investors own 99.12% of the company’s stock.

Innoviva Price Performance

Shares of INVA opened at $19.03 on Monday. The firm has a market cap of $1.35 billion, a PE ratio of 9.56, a P/E/G ratio of 4.16 and a beta of 0.38. The company has a current ratio of 15.44, a quick ratio of 14.58 and a debt-to-equity ratio of 0.23. The firm has a fifty day simple moving average of $20.70 and a two-hundred day simple moving average of $21.85. Innoviva, Inc. has a 1-year low of $18.66 and a 1-year high of $25.15.

Innoviva (NASDAQ:INVA – Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of $0.52 by ($1.55). The firm had revenue of $106.12 million for the quarter, compared to the consensus estimate of $115.31 million. Innoviva had a net margin of 44.13% and a return on equity of 22.91%. On average, equities analysts anticipate that Innoviva, Inc. will post 1.52 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have commented on INVA. Cantor Fitzgerald reduced their target price on Innoviva from $36.00 to $34.00 and set an “overweight” rating for the company in a report on Friday, August 7th. Oppenheimer lowered their price target on Innoviva from $35.00 to $34.00 and set an “outperform” rating on the stock in a report on Thursday, November 5th. Wall Street Zen downgraded Innoviva from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Weiss Ratings raised Innoviva from a “hold (c+)” rating to a “buy (b)” rating in a research report on Monday, November 9th. Finally, Zacks Research upgraded Innoviva from a “strong sell” rating to a “hold” rating in a report on Monday, August 31st. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Innoviva presently has a consensus rating of “Moderate Buy” and a consensus target price of $39.00.

View Our Latest Stock Analysis on Innoviva

About Innoviva

(Free Report)

Innoviva, Inc. is a biopharmaceutical company with two main areas of activity: royalty interests in respiratory medicines developed with GSK and the development and commercialization of specialty medicines. Its respiratory-related royalties include products such as Trelegy Ellipta, Anoro Ellipta and Breo Ellipta, which are used to treat chronic obstructive pulmonary disease and asthma and are marketed by GSK. Through its specialty therapeutics operations, Innoviva focuses on medicines for serious infections and other acute-care conditions.

Featured Stories

Institutional Ownership by Quarter for Innoviva (NASDAQ:INVA)

Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.